HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A new mechanism regulating the initiation of allergic airway inflammation.

AbstractBACKGROUND:
The earliest immune events induced by allergens are poorly understood, yet are likely essential to understanding how allergic inflammation is established.
OBJECTIVE:
We sought to describe the earliest signaling events activated by allergen and determine their significance to allergic inflammation.
METHODS:
A fungal-associated allergenic proteinase (FAP) or ovalbumin was administered once intranasally to wild-type mice to determine their ability to induce allergy-associated genes and initiate allergic lung inflammation. Mice deficient in recombinase activating gene 1, C3a, the C3a anaphylatoxin receptor, and MyD88 were challenged similarly to understand the requirement of these molecules and T and B cells for allergic inflammation. Adoptive T-cell transfer experiments were further performed to determine whether signal transducer and activator of transcription 6 (STAT6) was required for cell recruitment and allergic inflammation.
RESULTS:
FAP, but not ovalbumin, induced eosinophilic airway inflammation and lung IL-4 production in the absence of adaptive immune cells after the transcriptional induction of allergy-specific airway chemokines. Allergen-mediated chemokine secretion and innate allergic lung inflammation occurred in the absence of STAT6, recombinase activating gene 1, C3a, C3a anaphylatoxin receptor, Toll-like receptor 4, and MyD88 but required intact proteinase activity. Furthermore, FAP induced recruitment of T(H)2 cells and eosinophils to lungs independently of STAT6, which was previously thought to be required for T(H)2 cell homing.
CONCLUSION:
FAP induces allergic lung inflammation through a previously unrecognized innate immune signaling mechanism.
CLINICAL IMPLICATIONS:
These findings reveal a new paradigm for understanding how allergic inflammation begins and suggest novel possibilities for the prevention and treatment of allergic diseases, such as asthma.
AuthorsAttila Kiss, Martin Montes, Sarat Susarla, Elin A Jaensson, Scott M Drouin, Rick A Wetsel, Zhengbin Yao, Rachel Martin, Nabeel Hamzeh, Rebecca Adelagun, Sheila Amar, Farrah Kheradmand, David B Corry
JournalThe Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 120 Issue 2 Pg. 334-42 (Aug 2007) ISSN: 0091-6749 [Print] United States
PMID17544098 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Allergens
  • Chemokines
  • Fungal Proteins
  • Receptors, Complement
  • STAT6 Transcription Factor
  • Toll-Like Receptor 4
  • Interleukin-4
  • Complement C3a
  • Peptide Hydrolases
Topics
  • Allergens (immunology)
  • Animals
  • Aspergillus oryzae (enzymology)
  • Chemokines (metabolism)
  • Complement C3a (metabolism)
  • Eosinophils (pathology)
  • Fungal Proteins (immunology)
  • Gene Expression Regulation
  • Hypersensitivity (complications, genetics, immunology)
  • Interleukin-4 (biosynthesis)
  • Lung (pathology)
  • Mice
  • Mice, Inbred Strains
  • Peptide Hydrolases (immunology, metabolism)
  • Pneumonia (etiology, pathology)
  • Receptors, Complement (metabolism)
  • STAT6 Transcription Factor (metabolism)
  • Signal Transduction
  • Th2 Cells (pathology)
  • Toll-Like Receptor 4 (metabolism)
  • Transcription, Genetic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: